The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

HHMI Investigator Kevan Shokat and his lab are charting new therapies to outmaneuver drug resistance and better target common cancer cell mutations.

ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, ...

Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...

Daraxonrasib received FDA breakthrough therapy designation for metastatic PDAC with KRAS G12 mutations, expediting its development. The designation is based on promising phase 1 trial results, with ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ...